Hologic Continues Spending Spree With $230M Tuck-In Acquisition Of Biotheranostics
Hologic’s recent buy-outs put it in a strengthened growth and competitive position beyond COVID.
You may also be interested in...
The VC market during 2021 was frantic, cash rich and oftentimes appeared to be acting on a “buy now, ask questions later” mentality. With COVID headwinds dwindling, and emerging market uncertainties, what will 2022 bring?
2021 was a busy year in the medtech investment space. How will 2022 compare?
Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.